





FINAL PROGRAMME

FRIDAY 31 JANUARY 2025

09:30-12:00 Breast Cancer Task Force - moderators: Hans Wildiers and Ahmad Awada

09:30 Early resistance to (neo)adjuvant systemic therapy in TNBC - Yannick Van Herck, UZ Leuven

10:00 What after resistance to CDK4/6i in luminal breast cancer? - Andrea Gombos, Institut Jules Bordet

10:30 How to refine the use of gene expression profiling in clinical practice? - Eline Naert, UZ Gent

11:00 MEMBERS ONLY

Open group discussion about standard practice, clinical trials and organizational aspects of breast cancer care - Ahmad Awada, CHIREC and Hans Wildiers, UZ Leuven

12:00-12:30 General Assembly MEMBERS ONLY

12:30-13:00 Lunchtime Satellite Symposium by Nutricia

Cancer Cachexia management in Belgium — from scientific evidence to practical implementation, the time is now - Elisabeth De Waele, UZ Brussel

13:00-14:00 Break & Poster viewing

14:00-15:30 Update in rare cancers - moderators: Christine Gennigens and Eline Naert

14:00 Sarcoma - Patrick Schöffski, UZ Leuven

14:25 Neuroendocrine tumours - Willem Lybaert, VITAZ/UZA

14:50 Glioblastoma - Pierre Frères, CHU de Liège

15:15 Interactive discussion between panel and public - Q&A

15:30-16:00 Award session - moderator: Kevin Punie

- Pfizer Oncology Award Presentation 2022
 - 15:31 Understanding and mitigating risks that can compromise the quality and safety of anticancer biotherapeutics due to pneumatic tube transport in hospitals Tiene Bauters, UZ Gent
 - 15:38 Implementation of interactive stratification tools for penile cancer patients to determine their individual need for patient education or psycho-sexual counselling Camille Roumieux, KU Leuven
- Gilead Breast Cancer Research Awards 2025 & presentation by Laureates 2023
 - 15:45 Announcement Awardees 2025
 - Brief project overview by Laureates 2023
 - 15:50 1st place: Glenn Broeckx, Ziekenhuis aan de Stroom
 - 15:55 2nd place: Elisa Agostinetto, Institute Jules Bordet

16:00-16:30 Break & Poster viewing

16:30-18:00 Proffered papers by junior members - moderators: Cédric Van Marcke and Mariana Brandao

16:30 Role of eosinophils in clear-cell renal cell carcinoma - Marie Gilon, CHU de Liège

16:40 Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors - Mireille Langouo Fontsa, Institut Jules Bordet

16:50 Early LAG-3 and PD-L1 expression on T cells predict durable response to anti-PD-1 treatment in metastatic melanoma - Michael Saerens, UGent

17:00 Systemic immune cell omics as non-invasive predictors of immunotherapy (nipit) response and toxicity - Eufra Van Damme, UGent

17:10 Hereditary breast cancer beyond BRCA: clinicopathological characteristics and long-term outcomes - Kwinten Dejaegher, UZ Leuven

17:20 Three-year experience of BITOX: the Belgian multidisciplinary ImmunoTOXicity board, a nationwide initiative of the Belgian Society of Medical Oncology (BSMO) - Marthe Verhaert, UZ Brussel

17:30 Acquired Hemophilia due to Immune Checkpoint Inhibitors: A Case Series Introducing Emicizumab Treatment -Louis Wolff, Institut Jules Bordet

17:40 Association between neoadjuvant Paclitaxel dose-intensity and outcomes in early triple negative and HER2 positive breast cancer - François Zammit, UCLouvain

18:00-18:15 Summary and closing day 1 - Evandro de Azambuja, BSMO President







SATURDAY 1 FEBRUARY 2025

08:30-08:45 A brief recap of day 1 for those who missed it - Barbara Brouwers

08:45-09:30 Supportive Care Task Force - moderator: Florence Van Ryckeghem

08:45 Update in oncogeriatrics - Lore Decoster, UZ Brussel

09:07 Vaccination strategies in patients with cancer - Marie-Angélique De Scheerder, UZ Gent

09:30-10:00 Keynote lecture: Emerging treatments in GU cancer - Bertrand Tombal, Cliniques Universitaires Saint-Luc

10:00-10:30 What you should not have missed in 2024 - Luc Dirix, Ziekenhuis aan de Stroom

10:30-11:00 Break & Poster viewing

11:00-12:30 Academic session - moderators: Willem Lybaert and Annelies Verbiest

11:00 Challenges and opportunities in care of young patients with cancer - Matteo Lambertini, University of Genova — IRCCS Ospedale Policlinico San Martino, Italy

11:30 The wave of radioligands in oncology - Vanessa Schelfhout, AZ Sint-Jan

12:00 The use of surrogate endpoints and ESMO MCBS for drug approval - Martine Piccart, Institut Jules Bordet

12:30-12:45 Best junior abstracts ceremony and closing remarks - Cédric Van Marcke and Mariana Brandao

12:45-13:00 Closing remarks - Evandro de Azambuja, BSMO President

13:00-14:00 Break & Poster viewing

14:00-14:05 Introduction - Marthe Verhaert, UZ Brussel

14:05-15:05 BSMO Young Oncologists Committee (YOC) session - Part 1

- moderators: Marthe Verhaert and Nicolas Delhez

14:05 What can the advances and the setbacks of the past teach us about the future? - a brief story of cancer medical treatment - Martine Piccart, Institut Jules Bordet

14:35 Let's rediscover the paraneoplastic syndromes - Anne-Pascale Meert, Institut Jules Bordet

15:05-15:35 Break & Poster viewing

15:35-16:35 BSMO Young Oncologists Committee (YOC) session - Part 2

- moderators: Marthe Verhaert and Nicolas Delhez

15:35 Long term cardiovascular complications among survivors: who needs prevention?

- Berlinde von Kemp, UZ Brussel

16:05 Should we screen patients for other (primary) cancer? Is there a place for prevention and interception in this specific population? - Pamela Abdayem, Gustave Roussy

16:35-17:00 Closing remarks - Anouk Goudsmit, Institut Jules Bordet

17:00-17:30 YOC farewell